# US 2025/0144206 A1 · Methods Of Treatment Of Pterygium Using An Anti-VEGF Agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144206 A1
- Document ID: US20250144206A1
- Status: Published application
- Kind: A1
- Application number: 18/800,691
- Filed: 2024-08-12
- Published: 2025-05-08
- Earliest claimed: 2012-12-28
- Assignees: Cellviva, LLC
- Applicants: Cellviva, Inc.
- Inventors: Randal Tanh Hoang Pham
- Web page: https://patentgrep.com/patent/US20250144206A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.

## Claims

### Claim at position 1

-11. (canceled)

### Claim 12

A method of preventing pterygium recurrence in a patient in need thereof; wherein the patient has undergone pterygium removal in an eye at least once; comprising:
a. treat the patient's eye with a topical anesthetic; and
b. administer into the eye of the patient an anti-VEGF agent,
wherein the administering of the anti-VEGF agent prevents pterygium recurrence for at least 1 month in the patient's eye post-surgical removal.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pterygium does not recur in the eye of the patient for at least 6 months.

### Claim 14 (depends on 12)

The method of claim 12, wherein the pterygium does not recur in the eye of the patient for at least 12 months.

### Claim 15 (depends on 12)

The method of claim 12, wherein the Anti-VEGF agent is injected into the conjunctiva.

### Claim 16 (depends on 12)

The method of claim 12, wherein the Anti-VEGF agent is a small molecule.

### Claim 17 (depends on 12)

The method of claim 12, wherein the Anti-VEGF agent is an antibody.

### Claim 18 (depends on 17)

The method of claim 17, wherein the antibody is ranibizumab or bevacizumab.

### Claim 19 (depends on 12)

The method of claim 12, wherein neovascularization of the pterygium is prevented by the administering of the anti-VEGF agent.

### Claim 20 (depends on 12)

The method of claim 12, wherein the method further comprises administering an NSAID.

### Claim 21 (depends on 20)

The method of claim 20, wherein the NSAID is selected from: diclofenac, aspirin, ibuprofen, naproxen, indomethacin, meloxicam, piroxicam, mefenamic acid, celecoxib, etoricoxib, nabumetone, diflunisal, salsalate, meclofenamate, oxaprozin, and etodolac.

### Claim 22 (depends on 12)

The method of claim 12, wherein the method further comprises administering steroids.

### Claim 23 (depends on 12)

The method of claim 12, wherein the method further comprises tamponading bleeding with Q-tips®.

### Claim 24 (depends on 12)

The method of claim 12, wherein the method further comprises injecting the anti-VEGF agent into areas adjacent to vascular growth.

### Claim 25

A method for treating pterygium recurrence comprising administering to an affected eye of a patient in need of such treatment, ranibizumab and an NSAID; wherein the administering prevents pterygium recurrence for at least 1 month in the patient's eye.

### Claim 26 (depends on 25)

The method of claim 25, wherein there are at least two administrations of the ranibizumab.

### Claim 27 (depends on 26)

The method of claim 26, wherein the at least two administrations of the ranibizumab occur on separate days.

### Claim 28 (depends on 25)

The method of claim 25, wherein there are at least two administrations of an NSAID.

### Claim 29 (depends on 28)

The method of claim 28, wherein the NSAID is selected from: diclofenac, aspirin, ibuprofen, naproxen, indomethacin, meloxicam, piroxicam, mefenamic acid, celecoxib, etoricoxib, nabumetone, diflunisal, salsalate, meclofenamate, oxaprozin, and etodolac.

### Claim 30 (depends on 25)

The method of claim 25, wherein the method further comprises surgically removing the pterygium from the affected eye.
